These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35879379)

  • 1. The clinical significance of BRAFV600E mutations in pediatric papillary thyroid carcinomas.
    Li Y; Wang Y; Li L; Qiu X
    Sci Rep; 2022 Jul; 12(1):12674. PubMed ID: 35879379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single BRAFV600E mutation is not associated with aggressive biological behavior in adolescent and pediatric papillary thyroid carcinoma.
    Zhou B; Lu X; Hei H; Zhang S; Li Y; Fang J; Qin J; Ge H
    Cancer Cytopathol; 2023 Nov; 131(11):716-723. PubMed ID: 37519275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAFV600E mutation is associated with increased prevalence of contralateral lymph-node metastases in low and low-to-intermediate risk papillary thyroid cancer.
    Campennì A; Ruggeri RM; Giuffrè G; Siracusa M; Alibrandi A; Cardile D; La Torre F; Lanzafame H; Giacoppo G; Ieni A; Trimarchi F; Tuccari G; Baldari S
    Nucl Med Commun; 2021 Jun; 42(6):611-618. PubMed ID: 33625185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated BANCR expression levels have different effects on papillary thyroid carcinoma progression depending on the presence of the BRAFV600E mutation.
    Stojanović S; Šelemetjev S; Đorić I; Rončević J; Janković Miljuš J; Živaljević V; Išić Denčić T
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1835-1842. PubMed ID: 32651027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: A systematic review and meta-analysis.
    Chen B; Shi Y; Xu Y; Zhang J
    Clin Endocrinol (Oxf); 2021 May; 94(5):731-742. PubMed ID: 32816325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating BRAF
    Zhang Z; Zhang X; Yin Y; Zhao S; Wang K; Shang M; Chen B; Wu X
    BMC Cancer; 2022 Apr; 22(1):461. PubMed ID: 35473554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The synergic effect of BRAF
    Qu HJ; Qu XY; Hu Z; Lin Y; Wang JR; Zheng CF; Tan Z
    Endocr J; 2018 Jan; 65(1):113-120. PubMed ID: 29070763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
    Shi C; Guo Y; Lv Y; Nanding A; Shi T; Qin H; He J
    PLoS One; 2016; 11(12):e0167414. PubMed ID: 27936049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF
    Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J
    World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF analysis by fine needle aspiration biopsy of thyroid nodules improves preoperative identification of papillary thyroid carcinoma and represents a prognostic factor. A mono-institutional experience.
    Pelizzo MR; Boschin IM; Barollo S; Pennelli G; Toniato A; Zambonin L; Vianello F; Piotto A; Ide EC; Pagetta C; Sorgato N; Torresan F; Girelli ME; Nacamulli D; Mantero F; Mian C
    Clin Chem Lab Med; 2011 Feb; 49(2):325-9. PubMed ID: 21175381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma.
    Choi YW; Kim YH; Lee J; Soh EY; Park TJ; Kim JH
    Hum Pathol; 2015 Oct; 46(10):1557-65. PubMed ID: 26297257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Clinicopathological Results of Thyroid Cancer With BRAFV600E Mutation in the Young Population of Fukushima.
    Iwadate M; Mitsutake N; Matsuse M; Fukushima T; Suzuki S; Matsumoto Y; Ookouchi C; Mizunuma H; Nakamura I; Nakano K; Sakamoto A; Hirokawa M; Ito M; Naganuma H; Hashimoto Y; Shimura H; Yamashita S; Suzuki S
    J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32827026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiomics in predicting mutation status for thyroid cancer: A preliminary study using radiomics features for predicting BRAFV600E mutations in papillary thyroid carcinoma.
    Yoon JH; Han K; Lee E; Lee J; Kim EK; Moon HJ; Park VY; Nam KH; Kwak JY
    PLoS One; 2020; 15(2):e0228968. PubMed ID: 32053670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.
    Liu RT; Chen YJ; Chou FF; Li CL; Wu WL; Tsai PC; Huang CC; Cheng JT
    Clin Endocrinol (Oxf); 2005 Oct; 63(4):461-6. PubMed ID: 16181240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis.
    Kim SK; Song KH; Lim SD; Lim YC; Yoo YB; Kim JS; Hwang TS
    Thyroid; 2009 Feb; 19(2):137-41. PubMed ID: 19014278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
    Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
    Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Correlation between conventional ultrasound features and BRAFV600E gene mutation and central lymph node metastasis in thyroid papillary carcinoma].
    Zhang J; Feng Y; He X; Bai Q; Lv Y; Sun K; Qi M
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2022 Mar; 36(3):184-188. PubMed ID: 35193339
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma.
    Kim YS; Kim JS; Bae JS; Park WC
    World J Surg Oncol; 2013 May; 11():99. PubMed ID: 23687957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
    Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
    APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A different prognostic value of BRAFV600E mutation positivity in various age groups of patients with papillary thyroid cancer.
    Takacsova E; Kralik R; Waczulikova I; Zavodna K; Kausitz J
    Neoplasma; 2017; 64(1):156-164. PubMed ID: 27881018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.